Abstract
OBJECTIVES: In the present study, we have tested whether MRI T(1) relaxation time is a sensitive marker to detect early stages of amyloidosis and gliosis in the young 5xFAD transgenic mouse, a well-established animal model for Alzheimer's disease. MATERIALS AND METHODS: 5xFAD and wild-type mice were imaged in a 4.7 T Varian horizontal bore MRI system to generate T(1) quantitative maps using the spin-echo multi-slice sequence. Following immunostaining for glial fibrillary acidic protein, Iba-1, and amyloid-β, T(1) and area fraction of staining were quantified in the posterior parietal and primary somatosensory cortex and corpus callosum. RESULTS: In comparison with age-matched wild-type mice, we observed first signs of amyloidosis in 2.5-month-old 5xFAD mice, and development of gliosis in 5-month-old 5xFAD mice. In contrast, MRI T(1) relaxation times of young, i.e., 2.5- and 5-month-old, 5xFAD mice were not significantly different to those of age-matched wild-type controls. Furthermore, although disease progression was detectable by increased amyloid-β load in the brain of 5-month-old 5xFAD mice compared with 2.5-month-old 5xFAD mice, MRI T(1) relaxation time did not change. CONCLUSIONS: In summary, our data suggest that MRI T(1) relaxation time is neither a sensitive measure of disease onset nor progression at early stages in the 5xFAD mouse transgenic mouse model.